These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 7502052)

  • 1. Attenuated retrovirus vaccines and AIDS.
    Kestler HW; Jeang KT
    Science; 1995 Nov; 270(5239):1219; author reply 1220-2. PubMed ID: 7502052
    [No Abstract]   [Full Text] [Related]  

  • 2. Attenuated HIV vaccine: caveats.
    Ruprecht RM; Baba TW; Liska V
    Science; 1996 Mar; 271(5257):1790-2. PubMed ID: 8596941
    [No Abstract]   [Full Text] [Related]  

  • 3. A conditionally replicating virus as a novel approach toward an HIV vaccine.
    Das AT; Verhoef K; Berkhout B
    Methods Enzymol; 2004; 388():359-79. PubMed ID: 15289083
    [No Abstract]   [Full Text] [Related]  

  • 4. Naturally attenuated HIV--lessons for AIDS vaccines and treatment.
    Collins KL; Nabel GJ
    N Engl J Med; 1999 Jun; 340(22):1756-7. PubMed ID: 10352170
    [No Abstract]   [Full Text] [Related]  

  • 5. Attenuated and wild-type HIV-1 infections and long terminal repeat-mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo.
    Kent SJ; Cameron PU; Reece JC; Thompson PR; Purcell DF
    Virology; 2001 Aug; 287(1):71-8. PubMed ID: 11504543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Australia reports on AIDS: nef deletions, live vaccines, Chinese travelers.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):6-12, 40. PubMed ID: 11363347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1999: a time to re-evaluate AIDS vaccine strategies.
    Ruprecht RM; Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Xu W
    J Hum Virol; 2000; 3(2):88-93. PubMed ID: 10850895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a selectable nef-defective live-attenuated human immunodeficiency virus expressing Escherichia coli gpt gene.
    Tanuri A; Jesus da Costa L; Brindeiro R; Ramos CA; Pau CP; Rayfield MA
    Virology; 2000 Mar; 268(1):79-86. PubMed ID: 10683329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV research and nef alleles.
    Science; 1991 Jul; 253(5018):366. PubMed ID: 1862334
    [No Abstract]   [Full Text] [Related]  

  • 10. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative importance and functional role of genetic elements targeted for a live attenuated AIDS vaccine.
    Lang SM; Desrosiers RC
    Antibiot Chemother (1971); 1996; 48():92-9. PubMed ID: 8726510
    [No Abstract]   [Full Text] [Related]  

  • 12. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.
    Scriba TJ; zur Megede J; Glashoff RH; Treurnicht FK; Barnett SW; van Rensburg EJ
    Vaccine; 2005 Jan; 23(9):1158-69. PubMed ID: 15629359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of HIV-1 and treatment strategies.
    Terwilliger EF
    Emerg Med Clin North Am; 1995 Feb; 13(1):27-42. PubMed ID: 7851319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
    Dai K; Liu Y; Liu M; Xu J; Huang W; Huang X; Liu L; Wan Y; Hao Y; Shao Y
    Vaccine; 2008 Sep; 26(39):5062-71. PubMed ID: 18573290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.
    Kjerrström A; Hinkula J; Engström G; Ovod V; Krohn K; Benthin R; Wahren B
    Virology; 2001 May; 284(1):46-61. PubMed ID: 11352667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches for mucosal vaccines for AIDS: encapsidation and serial passages of poliovirus replicons that express HIV-1 proteins on infection.
    Morrow CD; Porter DC; Ansardi DC; Moldoveanu Z; Fultz PN
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S61-6. PubMed ID: 7865335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIDS vaccine development in primate models.
    Almond NM; Heeney JL
    AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
    [No Abstract]   [Full Text] [Related]  

  • 19. Attenuated retrovirus vaccines and AIDS.
    Marx PA
    Science; 1995 Nov; 270(5239):1219-20; author reply 1220-2. PubMed ID: 7502054
    [No Abstract]   [Full Text] [Related]  

  • 20. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
    Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
    Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.